Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus

New therapies are needed for patients with T-cell lymphoblastic leukemia (T-ALL) who do not respond to standard chemotherapy. Our previous studies showed that the mTORC1 inhibitor everolimus increases reactive oxygen species (ROS) levels, decreases the levels of NADPH and glucose-6-phosphate dehydro...

Descripción completa

Detalles Bibliográficos
Autores principales: Silic-Benussi, Micol, Sharova, Evgeniya, Corradin, Alberto, Urso, Loredana, Raimondi, Vittoria, Cavallari, Ilaria, Buldini, Barbara, Francescato, Samuela, Minuzzo, Sonia A., D’Agostino, Donna M., Ciminale, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045900/
https://www.ncbi.nlm.nih.gov/pubmed/36978873
http://dx.doi.org/10.3390/antiox12030625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045900/
https://www.ncbi.nlm.nih.gov/pubmed/36978873
http://dx.doi.org/10.3390/antiox12030625

Ejemplares similares